Immunotherapy Advances

Studying cancer vaccines? 🎯

Submit your latest research to our Cancer Vaccines Global Advances Special Collection!

Showcase personalized & off-the-shelf vaccines, clinical trials & more.

Deadline: Dec 2025

Learn more & submit: https://bit.ly/45mr1m8

#Immunotherapy

🔥 One of our most read articles!

Discover the unique role of DC3 dendritic cells in shaping immune responses within solid tumours and their impact on cancer therapy.

📖 Read more: https://bit.ly/3T2blRg

#CancerImmunology #DC3 #Immunotherapy

New open-access study reveals two distinct ways anti-CTLA-4 therapy can boost anti-tumour immunity, and highlights the surprising role of soluble CTLA-4 as both a challenge and a potential therapeutic tool.

🔗 https://bit.ly/4k6jcZj

#Immunotherapy #CTLA4 #CancerResearch

🚀 Immunobridging trials could fast-track cancer vaccine development by using immunological surrogates instead of lengthy Phase III trials.

Challenges remain in identifying reliable biomarkers, especially within the tumour microenvironment.

Read now: https://bit.ly/4faVpX0

Temporal control of cytokine production is lost in 2nd-gen CAR-T cells, says Patel et al. This could be key to understanding their efficacy and toxicity in cancer immunotherapy. 🧬

🔗 https://bit.ly/4lOLicw

#CancerImmunotherapy

Targeting monocyte dynamics in MS?

In Immunotherapy Advances, Bibi et al. explore how shifting monocytes from inflammatory to reparative states may reshape MS treatment strategies.

📘 https://bit.ly/3EXOfaV

#MS #Monocytes #Neuroinflammation

New research by Rui Zhao et al. shows that high anti-drug antibody (ADA) levels after 3 cycles of camrelizumab are linked to shorter survival in patients with advanced solid cancers.

📉 Higher ADA = lower drug levels = worse outcomes.

🔗 https://bit.ly/461mc5B

#Immunotherapy #CancerResearch

🔬 Call for papers: We invite submissions for a special collection on Immunotherapies for Inborn Errors of Immunity.

Explore genetics-guided, targeted treatments for primary immunodeficiency and immune dysregulation.

🗓️ Submit by Sept 2025

📖 Info: https://bit.ly/40o5kT8

#Immunotherapy

Mechanistic modelling reveals that both antigen-dependent and independent factors shape CAR T-cell dynamics in month-one lymphoma patients. IL-7/IL-15 levels and lymphodepletion matter more than CAR T-cell phenotype.

📖 Read: https://bit.ly/3U6fDY6

#Immunotherapy

A high-affinity TCRxCD3 bispecific (ImmTAC®) efficiently redirects T cells to kill PRAME+ tumor cells, even at low epitope density. Combination with anti-PD-1 restores activity in exhausted T cells.

One of the most read articles in ITA: https://bit.ly/40o5kT8

#immunology

Reintroducing Read & Publish with the BSI family journals | British Society for Immunology

Immunotherapy Advances publishes from discovery through to clinical trials - now more accessible than ever thanks to read & publish.

Make your science count beyond the lab bench.

Read more about read and publish here: https://bit.ly/4ksUbHJ

🧩 Antigen presentation is complex - but imaging is bringing clarity.

@doreenlau.bsky.social‬ & @timmunologist.bsky.social‬ review how advanced imaging illuminates T-cell–APC interactions, peptide-MHC dynamics, and more in cancer immunity.

📖 https://bit.ly/3TkIasN

#CancerImmunology

🧬 Better understanding of immune rejection and evasion is setting the stage for next-gen therapies.

Elizabeth Simpson reviews how foundational immunology is reshaping transplant and cancer treatment.

📖 https://bit.ly/44N141N

#TransplantImmunology #Immunotherapy

🚨 Last chance!

Just a few days left to submit to our Special Collection: Imaging in Immunotherapy.

Showcase your research in molecular imaging, immune monitoring, and image-guided drug delivery.

Deadline: June 2025 🧬🖼️ #Immunotherapy #MolecularImaging

📩 Submit now: https://bit.ly/4j8c265

🫁 New study: M2 macrophages ease asthma symptoms in mice by boosting IL-10⁺ B-cell production via the TGF-β & oxidative phosphorylation pathways.

💡 Highlights the regulatory role of macrophage–B cell interactions in asthma.

🔗 Read more: https://bit.ly/4kXzogj

🚨 Researchers at over 120 UK institutions can publish open access for free in Immunotherapy Advances!

No APC's, just impactful immunotherapy research shared with the world. 🌐 #OpenScience

🔗 Check eligibility here: bit.ly/4no9OTy

🔍 What do we really know about DC3s in solid tumors?

This new article explores the phenotype, function & impact of DC3s across cancers - highlighting their complex roles in both immunity & immunosuppression.

📖 Read it now: https://bit.ly/3T2blRg

#Immunotherapy

🚨 Submit to the Immunotherapies for Inborn Errors of Immunity special collection!

We’re looking for research & reviews on targeted treatments, molecular pathways, and novel therapies for genetic immune disorders.

🗓️ Deadline: Sept 2025

🔗 https://bit.ly/45mr1m8

It’s #CervicalScreeningAwarenessWeek 🎗️

Tumour-reactive plasma cells fight HPV-driven cancers by making antibodies against HPV E2 proteins - offering new hope for personalized immunotherapy.

📖 https://bit.ly/3SVZsMC

June is #MyastheniaAwarenessMonth 🧠 #MAM2025

Regulatory B cells (Bregs) are key to immune balance, but in #MyastheniaGravis & other autoimmune diseases, their function falters.

This review maps Breg heterogeneity & therapeutic potential.

📖 https://bit.ly/4n1l3AW

#Autoimmunity #Immunotherapy

We all know science is a team sport, and we're so proud to have an award that celebrates this.

The 2025 BSI Outstanding Team Award, sponsored by @imtadvances.bsky.social is… Southampton Antibody and Vaccine Group

🧪 New in Immunotherapy Advances: A scalable 3D in vitro model mimics CTL exhaustion, enabling deeper insight into T cell suppression and therapeutic response.

Essential reading for anyone developing CTL-targeting immunotherapies.

🔗 https://bit.ly/4e1appC

#Immunotherapy

⏳ Last chance to submit!

Our special collection on Imaging in Immunotherapy closes end of June 2025.

Don’t miss the opportunity to feature your research on molecular imaging, drug delivery & immune monitoring.

📢 Submit now: https://bit.ly/4j8c265

🎉 The 2025 Oxford Cancer Immuno-Oncology Network Symposium is in full swing! @oxfordcancer.bsky.social‬

If you're attending, stop by our stand to chat all things Immunotherapy Advances - we'd love to connect!

And we're off!!

@timmunologist.bsky.social opens our third annual OCION Symposium ‪@oxfordmathematics.bsky.social today!

Don't forget to visit our sponsors posters/exhibition stands.
@imtadvances.bsky.social (STAND)
@nanoporetech.com (STAND)
@Immunocore (POSTER)
@10xgenomics.bsky.social (STAND)

The 2025 Oxford Cancer Immuno-Oncology Network Symposium is in full swing!

If you're here with us today, don't forget to visit our sponsor's posters/exhibition stands, as well as our PPI team during the breaks!
@imtadvances.bsky.social
@nanoporetech.com
@Immunocore
@10xgenomics.bsky.social

🌟 Calling all women leaders in immunology!

The EJI Ita Askonas Prize 2025 offers €20,000 + ECI 2027 travel to outstanding female group leaders who have run an independent lab.

Apply or nominate a colleague via BSI by 20 June! Find out how to apply: https://bit.ly/4kzbwzu

Much progress in this field. Read more and contribute @imtadvances.bsky.social
The Imaging in Immunotherapy Special Collection closes end of June!

Got cutting-edge research on molecular imaging or image-guided drug delivery? Submit now and get extra promotion.

📩 More info:bit.ly/4j8c265

Durvalumab after chemoradiotherapy boosts survival in stage III NSCLC patients.
Real-world UK data supports PACIFIC trial findings. Treatment tolerance matters!

Explore here: https://bit.ly/43OIkyt

#Immunotherapy #CancerResearch

🚨 Last chance to submit! The Imaging in Immunotherapy Special Collection closes end of June!

Got cutting-edge research on molecular imaging or image-guided drug delivery? Submit now and get extra promotion.

📩 More info:https://bit.ly/4j8c265

#Immunotherapy #MolecularImaging